E
Overview
Emmes Group combines a contract research organization (CRO) with an AI arm to support clinical research globally. The CRO Emmes provides study design, patient recruitment, data collection, statistics, and regulatory support, while Veridix AI builds software tools to plan, manage, and analyze trials using artificial intelligence. It differentiates itself by offering both hands-on trial services and an integrated AI-powered platform, backed by a long history dating to 1977 and a global health focus. Its goal is to modernize clinical research to make trials faster, safer, and more accessible for patients around the world.
Work here?Claim your company
Simplify's take
What believers are saying
- On November 10, 2026, Emmes and MedGenome launched a rare-disease partnership.
- Emmes' August 2026 CEO change signals faster AI commercialization and tighter operating discipline.
- Emmes' 2026 rare-disease and cell-therapy push opens higher-margin sponsor work beyond federal contracts.
What critics are saying
- NCI and NHLBI budgets drive Emmes' core revenue; 2027 federal cuts hit renewals fast.
- Integration risk from Essex, VaxTRIALS, Orphan Reach, and MedGenome can dilute execution.
- CRO commoditization from ICON, IQVIA, and Parexel can compress pricing and slow growth.
What makes Emmes Group unique
- Emmes named Dr. Rama Kondru CEO on August 24, 2026, doubling down on AI-native CRO execution.
- Emmes spans government, biopharma, and rare-disease trials through Essex, VaxTRIALS, and Orphan Reach.
- Emmes supports 125+ cell and gene therapy trials, anchored by NHLBI and NCI networks.
Help us improve and share your feedback! Did you find this helpful?